For research use only. Not for therapeutic Use.
iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma[1][2].
| Catalog Number | M079375 |
| CAS Number | 18623-44-4 |
| Synonyms | 4-[(5Z)-5-[(3,4-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid |
| Molecular Formula | C16H17NO5S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H17NO5S2/c1-21-11-6-5-10(8-12(11)22-2)9-13-15(20)17(16(23)24-13)7-3-4-14(18)19/h5-6,8-9H,3-4,7H2,1-2H3,(H,18,19)/b13-9- |
| InChIKey | IJWKSBPTJQMUHJ-LCYFTJDESA-N |
| SMILES | COC1=C(C=C(C=C1)C=C2C(=O)N(C(=S)S2)CCCC(=O)O)OC |
| Reference | [1]. Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124. [2]. Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32(11):4697-707. |
